Prof. Noah Burns, Stanford University

Chairs’ Welcome

Dr. Bonnie Charpentier, Cytokinetics

ACS President’s remarks

Prof. Carolyn Bertozzi, Stanford University 

New therapeutic modalities from glycoscience

Dr. Mikiko Okumura, UC Berkeley, Maimone Group

Arenophile-mediated dearomative functionalization of simple arenes

Dr. John Morrow, UCSF,  Arkin Group

Using small molecules for 14-3-3/client stabilization in cancer

Dr. Samy Ponnusamy, MilliporeSigma

Green chemistry

Dr. Andrew Judd, AbbVie

Development of selective BCL-XL inhibitors and application of antibody-drug conjugates

Anna Elleman, Stanford, Du Bois Group

Spatiotemporal control of voltage-gated sodium channels

Dr. Colin Skepper, Novartis

Bacterial topoisomerase inhibitors addressing fluoroquinolone resistance

Caleb Karmel, UC Berkeley, Hartwig Group

Iridium-catalyzed silylation of aryl C-H bonds

Dr. Alan Northrup, Merck

Synthesis inspires and enables design: Discover of STING agonist MK-1454

Thomas O’Connor, UC Berkeley, Toste Group

Generation of chiral allenes through a Cu-catalyzed, asymmetric β-fluoride elimination

Prof. Bill Degrado, UCSF

De novo design of functional proteins

Ben Boswell, Stanford, Burns Group

Scalable, six-step synthesis of air-stable fluorinated polyacetylene enabled by mechanochemistry

Dr. David Siler, Gilead

Process development of new routes to a fluorinated nucleoside precursor of rovafovir etalafenamide, a reverse transcriptase inhibitor treatment of HIV-1

Dr. Xochina El Hilali-Pollard, UCSF,  Renslo Group

Stabilizing a proenzyme with small molecules – a new approach in Huntington’s disease?

Clayton Hardman, Stanford, Wender Group

Scalable synthesis of bryostatin-1 and analogs, leads for enhanced cancer immunotherapy

Prof. Richmond Sarpong, UC Berkeley

Break-it-to-make-it strategies for chemical synthesis inspired by complex molecules

​